University Ghent Hospital
Welcome,         Profile    Billing    Logout  
 0 Trials 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Langenhove, Tim Van
TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
3
1500
Europe, RoW
Donanemab, (LY3002813), Placebo
Eli Lilly and Company
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
04/27
04/27
NCT06120049: [18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD Vs. MSA and DLB Vs. AD

Recruiting
2/3
113
Europe
[18F]-MFBG PET CT, [18F]-FE-PE2I PET CT or PET MRI, [123I]-MIBG SPECT CT, [18F]-MFBG PET dosimetry scans
prof. dr. Koen Van Laere, University Hospital, Ghent, Fund for Scientific Research, Flanders, Belgium, KU Leuven, Universitaire Ziekenhuizen KU Leuven
Parkinson Disease, Dementia with Lewy Bodies, MSA - Multiple System Atrophy, Alzheimer Disease
07/26
07/26
MoCA-HI, NCT06400173: Validation Of The Flemish Montreal Cognitive Assessment (MoCA) For Persons With Hearing Impairment

Recruiting
N/A
450
Europe
Cognitive screening, Audiological Assessment
University Ghent, University Hospital, Ghent
Dementia, Hearing Loss
12/25
12/25

Download Options